Celgene Corp. (CELG)

98.67
0.07 0.07
NASDAQ : Health Technology
Prev Close 98.60
Open 98.60
Day Low/High 98.17 / 98.85
52 Wk Low/High 58.59 / 99.36
Volume 3.35M
Avg Volume 3.82M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 69.73B
EPS 5.70
P/E Ratio 13.30
Div & Yield N.A. (N.A)
Celgene Provides Update On ABRAXANE® Combination Therapy In The Treatment Of Metastatic Triple-Negative Breast Cancer And Pancreatic Cancer

Celgene Provides Update On ABRAXANE® Combination Therapy In The Treatment Of Metastatic Triple-Negative Breast Cancer And Pancreatic Cancer

Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.

Celgene Submits Application To EMA For Ozanimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Celgene Submits Application To EMA For Ozanimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS).

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.

The Real Money Post Industrial Average Gains More Ground in February

The Real Money Post Industrial Average Gains More Ground in February

However, the RMPIA did not see as much improvement last month as some other market indices.

U.S. FDA Grants Priority Review For Fedratinib New Drug Application In Myelofibrosis

U.S. FDA Grants Priority Review For Fedratinib New Drug Application In Myelofibrosis

Celgene Corporation (NASDAQ:CELG) today announced the U.S.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Celgene Shares Slide as Key Bristol-Myers Investor Queries $74 Billion Takeover

Celgene Shares Slide as Key Bristol-Myers Investor Queries $74 Billion Takeover

Celgene shares traded sharply lower Thursday after one of Bristol-Myers Squibb's key investors said it $74 billion takeover bid for the cancer drug specialist was too risky and expensive.

Celgene Corporation Announces Key Regulatory Updates For REVLIMID® In Lymphoma And Luspatercept In MDS And Beta-Thalassemia

Celgene Corporation Announces Key Regulatory Updates For REVLIMID® In Lymphoma And Luspatercept In MDS And Beta-Thalassemia

Celgene Corporation (NASDAQ:CELG) today announced that the U.S.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Report Says Starboard Value Takes Stake in Bristol-Myers

Report Says Starboard Value Takes Stake in Bristol-Myers

Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.

Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg

Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg

News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

RMPIA soared 9.9% for the month, led by 11 double-digit gainers.

Wall Street Futures Mixed Amid 'Super Thursday' Earnings, 'Patient' Fed Tailwind

Wall Street Futures Mixed Amid 'Super Thursday' Earnings, 'Patient' Fed Tailwind

U.S. stocks look set for a mixed open Thursday, amid the busiest reporting session of the earnings season, even as global markets extend gains after the Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

Many see the Fed as done for the year. Never assume. Read the words as they are written.

Celgene Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Celgene Reports Fourth Quarter And Full Year 2018 Operating And Financial Results

Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018.

Global Stocks Gain as 'Patient' Fed, Strong U.S. Earnings Keep Bulls in Charge

Global Stocks Gain as 'Patient' Fed, Strong U.S. Earnings Keep Bulls in Charge

Global stocks extended gains Thursday, with markets in Asia rising to the highest level in four months, after the U.S. Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

TheStreet Quant Rating: C+ (Hold)